Economic impact of severe asthma in Spain: multicentre observational longitudinal study

Moreno, Carlos Melero; Quirce, Santiago; Huerta, A.; Uría, Estefany; Cuesta, M.

doi:10.1080/02770903.2018.1499035

Cited by 24 publications

(19 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…10 As evidence of the high costs associated with severe stages of the disease, a recent Spanish study has estimated a mean annual direct cost per patient equal to €7472, and when indirect costs were considered, the total mean annual cost rose to €8554. 11 As regard Italy, severe refractory asthma, occurring in patients not achieving disease control despite high-intensity therapy, good adherence and proper inhalation technique, has been associated with annual costs per patient amounting to €2815, including drug treatment, hospitalization and outpatient services. 12 Moreover, findings of a recent online survey completed by employed adults in Brazil, Canada, Germany, Japan, Spain and the UK reported an impact on productivity at work caused by asthma in nearly threequarters of patients.…”

Section: Introductionmentioning

confidence: 99%

<p>Omalizumab for Severe Allergic Asthma Treatment in Italy: A Cost-Effectiveness Analysis from PROXIMA Study</p>

Canonica¹,

Colombo²,

Rogliani³

et al. 2020

RMHP

View full text Add to dashboard Cite

Introduction: Inadequately controlled severe asthma patients require additional therapy accounting for significant clinical and economic burden. Our analysis aims to determine the cost-effectiveness of omalizumab in the management of severe allergic asthma in Italy based on observational data from the PROXIMA study. Methods: Observational data on efficacy, healthcare resource utilization and changes in quality of life at 12 months after the initiation of omalizumab were examined to estimate the cost-effectiveness compared to pre-omalizumab period and results were expressed with Incremental Cost-Effectiveness Ratio (ICER). The cost-utility analysis estimated the cost per quality-adjusted life-year (QALY) gained. Direct health costs were assessed from the perspective of the Italian National Health Service (NHS). Results: Omalizumab reduced the incidence of exacerbations, number of hospitalizations, physician visits, and improved quality of life after 12 months of treatment. Omalizumab had a greater effectiveness than pre-omalizumab treatment involving 0.132 QALYs gained and led to a €3729 per patient reduction in direct healthcare costs, excluding the add-on treatment cost. Nevertheless, the addition of omalizumab cost led to €7478 increase in total direct costs with respect to preomalizumab period. Based on difference in total direct cost and difference in QALY between post and pre-omalizumab period, the ICER was €56,847. According to sensitivity analysis, omalizumab provided a cost-effective use of NHS resources, already at 20% discounted price. Conclusion: This study offers a real-world evidence of omalizumab effectiveness in Italy. Despite the high acquisition cost of the innovative drug, omalizumab is a sustainable treatment option for patients with uncontrolled severe allergic asthma.

show abstract

Section: Introductionmentioning

confidence: 99%

<p>Omalizumab for Severe Allergic Asthma Treatment in Italy: A Cost-Effectiveness Analysis from PROXIMA Study</p>

Canonica¹,

Colombo²,

Rogliani³

et al. 2020

RMHP

View full text Add to dashboard Cite

show abstract

“…If patients have persistent symptoms or exacerbations despite optimal therapy, all of the therapeutic repertoire is needed (Steps 5 and 6 of the Spanish Guideline for Asthma Management [GEMA], Step 5 of the Global Initiative for Asthma [GINA]) – the stage is classified as severe asthma 1,2. This category is associated to higher direct and indirect economic costs,3 lower quality of life, and health complications associated with the chronic use of OCS 4…”

Section: Introductionmentioning

confidence: 99%

Effectiveness and safety of mepolizumab in severe refractory eosinophilic asthma: results in clinical practice

Pérez

Contreras-Rey

Sánchez-Gómez

2019

DIC

View full text Add to dashboard Cite

Background Asthma is an inflammatory disease of the airways with symptoms that vary over time and intensity, sometimes leading to disability or even death. Eosinophilic asthma accounts for 25% of cases of severe asthma. It is mediated by eosinophils regulated by interleukin-5 (IL-5), the target of mepolizumab, which has been recently licensed as an add-on treatment of severe refractory eosinophilic asthma. The aim of this study was to evaluate the effectiveness and safety of mepolizumab in clinical practice. Methods A multicentre, retrospective, and descriptive study covering a year was conducted in a province of Spain with more than 500,000 inhabitants. Every patient prescribed with mepolizumab since its introduction into the hospital was included in the study. Clinical parameters were collected from the pharmacists’ counselling reports from electronic prescription software and electronic patient records. Effectiveness was assessed as a decrease in the exacerbation frequency and/or a reduction in the use of oral corticosteroids (OCS) compared to the previous year. Results A total of 25 patients were studied, but only 23 could be evaluated by the cut-off date. A decrease in the exacerbation frequency was observed in 19 (82.6%) patients, 11 of them without any exacerbation during the treatment. A relative reduction of 87% in the exacerbation rate per year was obtained. A total of 15 patients were on regular OCS – 9 patients (60%) reduced their average dose, whilst 4 (26.7%) patients completely abandoned OCS. Safety was evaluated based on reported adverse effects. Adverse events were observed in 12 patients, the most common being headache, arthralgia, and dizziness/nausea. Conclusion Mepolizumab has been shown to be effective based on the high decrease in the exacerbation frequency and reduced use of OCS. Reported adverse effects were mostly mild and appeared in half of the patients; some of the adverse events had not been previously described in pivotal trials.

show abstract

“…Melero Moreno et al, 2019). Effective and safe treatment, particularly for severe asthma, is recognized as an unmet need (Chung et al, 2014).…”

Section: Introductionmentioning

confidence: 99%

“…Effective and safe treatment, particularly for severe asthma, is recognized as an unmet need (Chung et al, 2014). Severe asthma with inadequate control is associated with high healthcare resources consumption (Chung et al, 2014;Melero Moreno et al, 2019) and substantial indirect costs (Puig-Junoy and Pascual-Argenté, 2017). Direct costs related to asthma management are mostly driven by medication costs, which are attributable to 45%-84% of direct costs in Europe, and 51%-68% in North America.…”

Section: Introductionmentioning

confidence: 99%

“…Direct costs related to asthma management are mostly driven by medication costs, which are attributable to 45%-84% of direct costs in Europe, and 51%-68% in North America. (Souliotis et al, 2017) Severe asthma patients have been estimated to accrue annual costs ranging between €7,411-10,199 per patient in Spain (Melero Moreno et al, 2019).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Cost-effectiveness analysis of anti–IL-5 therapies of severe eosinophilic asthma in Spain

González‐Barcala

Muñoz

Mariscal

et al. 2021

Journal of Medical Economics

View full text Add to dashboard Cite

show abstract

Economic impact of severe asthma in Spain: multicentre observational longitudinal study

Abstract: Taking the social perspective, the economic impact of severe asthma in Spain was estimated to be €8554/patient/year.

Cited by 24 publications

References 25 publications

<p>Omalizumab for Severe Allergic Asthma Treatment in Italy: A Cost-Effectiveness Analysis from PROXIMA Study</p>

<p>Omalizumab for Severe Allergic Asthma Treatment in Italy: A Cost-Effectiveness Analysis from PROXIMA Study</p>

Effectiveness and safety of mepolizumab in severe refractory eosinophilic asthma: results in clinical practice

Cost-effectiveness analysis of anti–IL-5 therapies of severe eosinophilic asthma in Spain

Contact Info

Product

Resources

About